IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease
Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
"Kineret" (INN: Anakinra) neutralizes the biological activity of interleukin-1α (IL-1α) and
interleukin-1β (IL-1β) by the concurrent inhibition of binding to interleukin-1 receptor I
(IL-1RI). Interleukin-1 (IL-1) is the main pro-inflammatory cytokine that mediates many
cellular responses. Anakinra inhibits the reactions caused by IL-1 in vitro, including the
induction of nitric oxide and prostaglandin E2 and / or the formation of collagenase by
synovial cells, fibroblasts and chondrocytes. According to published data, patients with the
chronic granulomatous disease have an increased secretion of interleukin-1, which contributes
to the development of granulomatous inflammation. Blocking interleukin-1 reduces the activity
of the main pro-inflammatory complex - the inflammasomes, and also restores the autophagy
process impaired in patients with chronic granulomatous disease. In this way, inhibition of
the IL-1 receptor prevents the activation of innate immunity cells and prevents the
maintenance of pathological pro-inflammatory signaling in conditions of IL-1 overproduction.
The efficacy and safety of therapy with the above drug is based on the results of
international studies on the using of anakinra in patients with chronic granulomatous
disease.
Phase:
Early Phase 1
Details
Lead Sponsor:
Federal Research Institute of Pediatric Hematology, Oncology and Immunology